Mindset Pharma Inc
CNSX:MSET
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Mindset Pharma Inc
Mindset Pharma, Inc. is a pharmaceutical discovery and development company. The company is headquartered in Toronto, Ontario. The company went IPO on 2020-12-23. The firm is focused on developing patentable psychedelic compounds for the treatment of neurological and psychiatric disorders, with an initial focus on psilocybin-inspired new chemical entities (NCEs). Its drug development platform seeks to advance medicines based on psychedelic substances through rigorous scientific and clinical trials, performed by third-party contract research organizations. The firm intends to commercialize the psilocybin-inspired psychedelic medicines that it develops as regulated medicines.
Mindset Pharma, Inc. is a pharmaceutical discovery and development company. The company is headquartered in Toronto, Ontario. The company went IPO on 2020-12-23. The firm is focused on developing patentable psychedelic compounds for the treatment of neurological and psychiatric disorders, with an initial focus on psilocybin-inspired new chemical entities (NCEs). Its drug development platform seeks to advance medicines based on psychedelic substances through rigorous scientific and clinical trials, performed by third-party contract research organizations. The firm intends to commercialize the psilocybin-inspired psychedelic medicines that it develops as regulated medicines.
